Corient Private Wealth
AZN icon

Corient Private Wealth’s AstraZeneca AZN Stock Holding History

Corient Private Wealth’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.9M Sell
104,740
-165,174
-61% -$31.8M 0.03% 404
2025
Q4 		$38.3M Buy
269,914
+163,725
+154% +$28.7M 0.03% 419
2025
Q3 		$16.3M Buy
106,189
+9,334
+10% +$1.41M 0.03% 429
2025
Q2 		$13.5M Buy
96,855
+3,278
+4% +$459K 0.02% 460
2025
Q1 		$13.8M Sell
93,577
-5,052
-5% -$731K 0.02% 453
2024
Q4 		$12.6M Buy
98,629
+4,447
+5% +$623K 0.02% 464
2024
Q3 		$14.7M Sell
94,182
-8,545
-8% -$1.38M 0.02% 472
2024
Q2 		$16M Buy
102,727
+28,905
+39% +$4.35M 0.03% 430
2024
Q1 		$10M Sell
73,822
-79,242
-52% -$10.5M 0.02% 522
2023
Q4 		$20.6M Sell
153,064
-26,858
-15% -$3.49M 0.04% 381
2023
Q3 		$24.4M Buy
179,922
+68,292
+61% +$9.33M 0.06% 303
2023
Q2 		$16M Sell
111,630
-22
-0% -$3.24K 0.04% 387
2023
Q1 		$15.5M Buy
111,652
+14,418
+15% +$1.94M 0.04% 360
2022
Q4 		$13.2M Buy
+97,234
New +$12.2M 0.05% 325

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Corient Private Wealth's AZN Position: Q1 2026 in Review

Corient Private Wealth reduced its AstraZeneca (AZN) stake by 61% in Q1 2026, selling an estimated $31.8M and leaving 104,740 shares worth $19.9M. The position accounts for 0.03% of the portfolio, ranked #404.

Corient Private Wealth first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. The position peaked at $38.3M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Corient Private Wealth held 104,740 shares of AstraZeneca worth $19.9M as of Q1 2026.
  • Corient Private Wealth sold 165,174 AstraZeneca shares in Q1 2026, an estimated $31.8M.
  • AstraZeneca made up 0.03% of Corient Private Wealth's portfolio in Q1 2026, its #404 holding.
  • Corient Private Wealth first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's AstraZeneca position peaked at $38.3M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.